Strides Pharma Science Ltd

Strides Pharma Science Earnings Call: Key Takeaways

Strides delivered strong FY26 performance with Revenue at ₹48,587m, up 6.4%, and Operational PAT at ₹5,181m, growing 50% YoY driven by Ex-US market efficiency.

Strides Pharma Science Results Update

Strides reported strong FY26 performance with EBITDA reaching ₹9,253 million. The Board recommended a dividend of ₹5 per share, reflecting robust growth in Ex-US markets.

Strides Pharma Science Q4 FY26 Results: Net Profit ₹129.3 Cr, Up 51.1% YoY

Strides Pharma Science Ltd reported revenue from operations of ₹1,324 Cr (+11.2% YoY) and net profit of ₹129.3 Cr (+51.1% YoY) for Q4 FY26.

Key figure

Net profit ₹129.3 Cr · +51.1% YoY

Strides Pharma Science Financial Results

Strides Pharma reported audited FY26 results and recommended a 50% final dividend. The proposed payout will result in an approximate cash outflow of ₹46.10 Crore.

Value

₹461.0 Cr

Strides Pharma Science Board Meeting Date

Strides Pharma Science scheduled a Board Meeting for May 18, 2026. Directors will consider FY26 audited financial results and recommend a final dividend.

Strides Pharma Science Q3 FY26 Results: Net Profit ₹208 Cr, Up 131.1% YoY

Strides Pharma Science Ltd reported net profit of ₹208 Cr (+131.1% YoY) for Q3 FY26.

Key figure

Net profit ₹208 Cr · +131.1% YoY